Financial Releases

MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the U.S. Food and Drug Administration ( FDA ) has performed a Pre-Approval Inspection

MENLO PARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Intersect ENT (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the Company has been added to the Russell 2000 ® index, effective as of the close of

MENLO PARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the closing of its initial public offering of 5,750,000 shares of

Underwriters Exercise Option for 537,300 Shares of Common Stock, Increasing Total Aggregate Proceeds to Approximately $103.0 Million MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and

Product Offers Targeted Relief for Managing Chronic Condition MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 11, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it has received approval from the